TrialInternational journal of cancer2025

Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial.

Milena Beierlein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.